Abstract
INTIMAL smooth muscle cell (SMC) proliferation dominates the early phase of healing after arterial endothelial injury1–6; what growth factors are responsible for this mitotic activity of an otherwise quiescent cell is not known. SMC growth in vitro is enhanced by platelet factors, insulin and lipoproteins7–11 and, according to some reports, can be diminished in vivo with various antiplatelet agents. Harker et al.6 have reported decreased myointimal thickening in homocystinaemic baboons treated with dipyridamole, and Friedman et al.11 and Moore et al.12 have reported suppression of SMC proliferation in the injured arteries of rabbits injected with anti-platelet serum. Intimal thickening was not diminished, however, in the injured carotid arteries of rats given various anti-platelet drugs13. Because the clotting system is inextricably linked to arterial injury and because thrombin is used to generate the platelet growth factor9 and may itself be a mitogen14,15, we speculated that heparin might inhibit myointimal thickening. We report here the use of heparin to suppress intimal SMC hyperplasia in a rat model of arterial endothelial injury and suggest possible mechanisms for the heparin effect.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Fishman, J. A., Ryan, G. B. & Karnovsky, M. J. Lab. Invest. 32, 339–351 (1975).
Clowes, A. W., Ryan, G. B., Breslow, J. L. & Karnovsky, M. J. Lab. Invest. 35, 6–17 (1976).
Stemerman, M. B. & Ross, R. J. exp. Med. 136, 769–789 (1972).
Bondjers, G. & Bjornheden, T. Atherosclerosis 12, 301–306 (1970).
Schwartz, S. M., Stemerman, M. B. & Benditt, E. P. Am. J. Path. 81, 15–42 (1975).
Harker, L. A., Ross, R., Slichter, S. J. & Scott, C. R. J. clin Invest. 58, 731–741 (1976).
Fisher-Dzoga, K., Chen, R. & Wissler, R. W. Adv. exp. Med. Biol. 43, 299–311 (1974).
Ross, R. & Glomset, J. A. Science 180, 1332–1339 (1973).
Ross, R., Glomset, J., Karija, B. & Harker, L. Proc. natn. Acad. Sci. U.S.A. 71, 1207–1210 (1974).
Stout, R. W., Bierman, E. L. & Ross, R. Circulat. Res. 36, 319–327 (1975).
Friedman, R. J., Stemerman, M. B., Spaet, T. H., Moore, S. & Gauldie, J. Fedn Proc. 35, 207, Abstr. (1976).
Moore, S., et al. Thromb. Haem. 35, 70–81 (1976).
Clowes, A. W. & Karnovsky, M. J. Lab. Invest. (in the press).
Chen, L. B. & Buchanan, J. M. Proc. natn. Acad. Sci. U.S.A. 72, 131–135 (1975).
Zetter, B. R., Chen, L. B., Sun, T. & Buchanan, J. M. J. Cell. Biol. 70 282a (1976).
Steiger, E., Vars, H. M. & Dudrick, S. J. Arch. Surg. 104, 330–332 (1972).
Lee, R. I. & White, P. D. Am. J. med. Sci. 145, 495–503 (1913).
Fischer, A. & Astrup, T. Proc. Soc. exp. Biol. Med. 38, 494–496 (1938).
Regelson, W. Adv. Chemother. 3, 303–371 (1968).
Jaques, L. B. Prog. med. Chem. 5, 139–198 (1967).
Heilbrunn, L. V. & Wilson, W. L. Proc. Soc. exp. Biol. Med. 70, 179–182 (1948).
Ross, R. & Glomset, J. A. New Engl. J. Med. 295, 369–377 (1976).
Rosenberg, R. D. New Engl. J. Med. 292, 146–151 (1975).
Essien, E. M., Kinlough-Rathbone, R., Moore, S. & Mustard, J. F. Thromb. Diath. Haemorrh. 34, 600, Abstr. (1975).
Pilcher, D. B. & Barker, W. F. Am. J. Surg. 120, 270–274 (1970).
Alrich, E. M. & Lehman, E. P. Surg. Gyn. Obs. 87, 26–30 (1948).
Stinchfield, F. E., Sankaran, B. & Samilson, R. J. Bone Jt Surg. 38 A, 270–282 (1956).
Ohwiler, D. A., Jurkiewicz, M. J., Butcher, Jr, H. R. & Brown, J. B. Surg. Forum 10, 301–303 (1959).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
CLOWES, A., KARNOWSKY, M. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 265, 625–626 (1977). https://doi.org/10.1038/265625a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/265625a0
This article is cited by
-
The effect of Substance P/Heparin conjugated PLCL polymer coating of bioinert ePTFE vascular grafts on the recruitment of both ECs and SMCs for accelerated regeneration
Scientific Reports (2019)
-
Recent alternative approaches of vascular drug-eluting stents
Journal of Pharmaceutical Investigation (2018)
-
Prophylactic Low Molecular Weight Heparin Improving Perinatal Outcome in Non-thrombophilic Placental-Mediated Complications
The Journal of Obstetrics and Gynecology of India (2016)
-
Mesoglycan attenuates VSMC proliferation through activation of AMP-activated protein kinase and mTOR
Clinical Hypertension (2015)
-
Early Results with the Use of Heparin-bonded Stent Graft to Rescue Failed Angioplasty of Chronic Femoropopliteal Occlusive Lesions: TASC D Lesions Have a Poor Outcome
CardioVascular and Interventional Radiology (2012)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.